Information Provided By:
Fly News Breaks for August 9, 2016
SPNC
Aug 9, 2016 | 09:12 EDT
Needham analyst Mike Matson downgraded Spectranetics to Buy from Strong Buy on valuation. Nonetheless, the analyst is more positive about its Stellarex's ability to take share in the drug-coated balloon market and the company's ability to sustain strong growth in the base Vascular Intervention business after meeting with Spectranetics' CEO Scott Drake and COO Shar Matin. The analyst has a $27 price target on the shares.
News For SPNC From the Last 2 Days
There are no results for your query SPNC
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.